Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Las Vegas Sands Corp. — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Las Vegas Sands Corp. trades at $37.07 (market cap $23.99B). The key difference: GE HealthCare Technologies Inc. Common Stock is the larger of the two by market cap, and Las Vegas Sands Corp. pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| GEHC | LVS | |
|---|---|---|
Market Cap | $31.07B | $23.99B |
Volume | 3,443,020 | 5,076,550 |
Sector | Health | Consumer Cyclical |
52-Week High | $88.16 | $69.49 |
52-Week Low | $59.48 | $35.81 |
Enterprise Value | $39.53B | $35.88B |
Dividend Yield | 0.23% | 3.24% |
Typical Hold Time | — | 73 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
LVS trades at $37.02, up 2.41% today, but faces bearish technical signals with strong selling pressure on moving averages. The company shows solid fundamentals with revenue growth from $13.02B in 2025 to projected $13.7B in 2026, net margins around 12.5%, and attractive valuation with P/E of 14.36. Recent earnings show mixed results with Q2 2026 missing expectations after two consecutive beats. Analysts maintain strong buy consensus with $58.89 price target representing 59% upside potential.
LVS presents compelling value with strong analyst support and reasonable valuations, though technical weakness and high debt levels pose near-term risks. The company's consistent revenue growth and Macao recovery provide upside catalysts, but investors should monitor debt management and gaming regulatory environment. The significant gap between current price and analyst targets suggests substantial potential reward for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
